• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.

作者信息

Xia Leiming, Tian Wanlu, Zhao Yiming, Jiang Lingling, Qian Wei, Jiang Lei, Ge Ling, Li Jianjun, Jin Fengbo, Yang Mingzhen

机构信息

Department of Hematology, the first affiliated hospital of Anhui Medical University, Hefei, Anhui, 230022, China.

Anhui Public Health Clinical Center, Hefei, Anhui, 230031, China.

出版信息

Signal Transduct Target Ther. 2023 May 3;8(1):176. doi: 10.1038/s41392-023-01394-8.

DOI:10.1038/s41392-023-01394-8
PMID:37130896
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10154410/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/488d/10154410/8977da317712/41392_2023_1394_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/488d/10154410/8977da317712/41392_2023_1394_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/488d/10154410/8977da317712/41392_2023_1394_Fig1_HTML.jpg

相似文献

1
Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.维奈托克与阿扎胞苷用于不适宜接受强化化疗的中国初治急性髓系白血病患者
Signal Transduct Target Ther. 2023 May 3;8(1):176. doi: 10.1038/s41392-023-01394-8.
2
[Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].维奈托克联合阿扎胞苷治疗老年急性髓系白血病或髓系肉瘤：三例报告及文献综述
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):694-696. doi: 10.3760/cma.j.issn.0253-2727.2020.08.016.
3
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
4
Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.维奈克拉与阿扎胞苷联合用药是复发/难治性急性髓系白血病患者移植策略的有效过渡方案。
Ann Hematol. 2021 Apr;100(4):1111-1113. doi: 10.1007/s00277-020-04333-7. Epub 2020 Nov 11.
5
Real-world treatment patterns of venetoclax and azacytidine therapy in Japanese patients with acute myeloid leukemia.日本急性髓系白血病患者中维奈克拉和阿扎胞苷治疗的真实世界治疗模式。
Ann Hematol. 2023 May;102(5):1283-1285. doi: 10.1007/s00277-023-05201-w. Epub 2023 Mar 29.
6
[Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].维奈克拉与阿扎胞苷治疗难治性和复发性急性髓系白血病的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2021 Oct 14;42(10):861-864. doi: 10.3760/cma.j.issn.0253-2727.2021.10.012.
7
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.VIALE-A研究中接受维奈克拉和阿扎胞苷治疗的急性髓系白血病患者缓解后血细胞减少的管理
Am J Hematol. 2022 Nov;97(11):E416-E419. doi: 10.1002/ajh.26692. Epub 2022 Sep 16.
8
Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia.在接受 venetoclax 和阿扎胞苷治疗的日本急性髓系白血病患者中，venetoclax 暴露过度与中性粒细胞减少症的持续时间延长有关。
Cancer Chemother Pharmacol. 2024 Aug;94(2):285-296. doi: 10.1007/s00280-024-04673-5. Epub 2024 May 23.
9
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.阿扎胞苷和维奈托克治疗不适合治疗的初治急性髓系白血病患者的成本效益。
Blood Adv. 2021 Feb 23;5(4):994-1002. doi: 10.1182/bloodadvances.2020003902.
10
Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.接受阿扎胞苷和维奈克拉治疗的复发/难治性白血病儿科患者的临床反应
Haematologica. 2023 Nov 1;108(11):3142-3147. doi: 10.3324/haematol.2022.282637.

引用本文的文献

1
Hypomethylating agent versus venetoclax combination: an electronic health records-based target trial emulation among Asian elderly patients with newly diagnosed acute myeloid leukaemia in Hong Kong.去甲基化药物与维奈克拉联合用药：香港新诊断急性髓系白血病亚洲老年患者基于电子健康记录的目标试验模拟
Ther Adv Hematol. 2025 Jul 4;16:20406207251346914. doi: 10.1177/20406207251346914. eCollection 2025.
2
Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities.维奈托克联合去甲基化药物用于急性髓系白血病诱导治疗的疗效及预后分析：一项关于适应证特异性分层、分子标志物和血液学毒性的多中心真实世界研究
Cancer Cell Int. 2025 Jul 1;25(1):241. doi: 10.1186/s12935-025-03858-z.
3

本文引用的文献

1
Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified.维奈托克联合阿扎胞苷或化疗用于未另行指定的难治性/复发性谱系不明确的急性白血病的疗效。
Exp Hematol Oncol. 2021 Sep 16;10(1):46. doi: 10.1186/s40164-021-00239-w.
2
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia.并非BCL2突变而是显性突变转换导致急性髓系白血病中获得性维奈托克耐药。
Biomark Res. 2021 May 1;9(1):30. doi: 10.1186/s40364-021-00288-7.
3
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia.维奈克拉联合低甲基化治疗急性髓系白血病有效性和安全性的Meta分析
Eur J Med Res. 2025 Apr 26;30(1):330. doi: 10.1186/s40001-025-02571-x.
4
Meta‑analysis of the efficacy of venetoclax and azacitidine combination therapy and azacitidine monotherapy for treating acute myeloid leukemia.维奈克拉与阿扎胞苷联合疗法及阿扎胞苷单药疗法治疗急性髓系白血病疗效的Meta分析
Exp Ther Med. 2024 Feb 26;27(4):164. doi: 10.3892/etm.2024.12452. eCollection 2024 Apr.
地西他滨和维奈克拉治疗异柠檬酸脱氢酶1/2突变的急性髓系白血病
Am J Hematol. 2021 May 1;96(5):E154-E157. doi: 10.1002/ajh.26122. Epub 2021 Feb 19.
4
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
5
Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.伴有阿扎胞苷的维奈托克治疗未经治疗的急性髓系白血病患者的真实世界经验。
Blood Adv. 2019 Oct 22;3(20):2911-2919. doi: 10.1182/bloodadvances.2019000243.